Long-term therapy of chronic delta hepatitis with peginterferon alfa


SUMMARY

Background
Chronic delta hepatitis virus (HDV) infection rapidly progresses to cirrhosis. Treatment with peginterferon for up to 2 years is often without durable response.

Aim
To examine the efficacy and safety of long-term peginterferon in achieving a durable response.

Methods
Treatment was initiated with 180 μg/week of peginterferon alfa-2a with titration to a maximal tolerable dose, for up to 5 years. Liver biopsies and hepatic venous pressure gradients (HVPG) were evaluated at baseline, 1, 3 and 5 years. The primary endpoint was histological improvement or loss of serum HDV and HBsAg at 3 years.

Results
Thirteen patients were treated for a median of 140 weeks (6–260) with an average peginterferon dose of 180 μg/week (90–270). At baseline, most had advanced disease (median Ishak fibrosis = 3) with portal hypertension (HVPG = 10.2 ± 6 mmHg). Five of 13 patients (39%) achieved the primary endpoint, with three seroconverting for HBsAg after 24, 37 and 202 weeks of treatment. Histological inflammation improved after 1 year, (median HAI: 10 vs. 7, P = 0.01) with persistence in 4/5 patients at 3 years (median HAI: 7.5). Greatest improvements occurred in the first year. Baseline bilirubin and HBsAg levels were significantly lower in virological responders than nonresponders. After 12 weeks, virological responders had a significant decline in HBsAg (1.5 log10 IU/mL, P = 0.05).

Conclusion
Despite increased doses and duration of therapy, treatment of chronic HDV with peginterferon remains unsatisfactory. Quantitative measures of HBsAg may be an important biomarker of early response to peginterferon therapy in chronic delta hepatitis virus infection.
INTRODUCTION

The hepatitis D (delta hepatitis) virus (HDV) is the smallest pathogenic animal virus known to infect humans with an estimated 15–20 million chronically infected worldwide. The virus is an incomplete RNA virus, which is composed of a 1.7 kb single-stranded circular genomic RNA, virally encoded small and large delta antigens, and a surrounding lipid envelope of hepatitis B surface antigen (HBsAg). Propagation in humans only occurs in individuals infected with hepatitis B virus (HBV), either via superinfection or co-infection.

The hepatitis D (delta hepatitis) virus infection has been described to be endemic in various regions throughout the world. Compared to patients mono-infected with HBV, patients co-infected with HDV suffer more severe chronic hepatitis and progress more rapidly to cirrhosis. In addition, those with HDV are at higher risk for hepatic decompensation leading to death and the development of hepatocellular carcinoma (HCC) compared to individuals with HBV alone. Thus, HDV shares epidemiological patterns and clinical features with hepatitis B, but tends to be more severe.

Currently, no satisfactory or FDA approved therapy exists for HDV infection. The American Association for the Study of Liver Diseases (AASLD) guidelines suggest the use of alpha interferon as therapy for chronic HDV infection. However, alpha interferon therapy is generally unsatisfactory and poorly tolerated; serum aminotransferase levels normalise in only 40–70% of treated patients and relapse occurs in 60–97% of patients. Long-term treatment with alpha interferon has been reported to be beneficial and preliminary evidence with 96 weeks of peginterferon-based therapy appears safe. Instances of a complete response to therapy, defined as a loss of HDV RNA and HBsAg and development of anti-HBs, have been reported, although rarely. Thus, standard preparations of alpha interferon are an unsatisfactory therapy for chronic hepatitis D and are limited by poor tolerance and a relatively low long-term response rate.

In this study, we examined the utility of long-term high-dose pegylated alpha interferon in patients with chronic hepatitis D and evaluated its effect on hepatic histology, safety and tolerability.

METHODS

Patients

Patients with chronic delta hepatitis with anti-HDV in serum and HDV antigen in liver tissue were eligible for this prospective, open-label, nonrandomised study of peginterferon treatment for up to 260 weeks. Inclusion criteria included: age ≥18 years, serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above the upper limit of normal (ALT >41 or AST >31 U/L) on an average of three determinations taken within 6 months before treatment, and a liver biopsy obtained within 12 months with a necroinflammatory score of at least 5 (out of 18) and at least 1 for hepatic fibrosis (out of 6) as scored using the Ishak modification of the HAI scoring system. All liver biopsies were interpreted by a single hepatopathologist (DEK) who was blinded to the clinical data. All patients had to have histological staining for HDV antigen. Hepatic venous pressure gradient (HVPG) measurements were obtained at the time of liver biopsy via the transjugular route with rigorous adherence to methodology as previously described. Exclusion criteria included evidence of other forms of liver disease, hepatocellular carcinoma, decompensated liver disease, human immunodeficiency virus (HIV) co-infection, active drug or alcohol abuse, any contraindication to peginterferon, and pregnancy or refusal to use adequate contraception during therapy.

All patients provided written, informed consent, and the study protocol and consent forms were approved by the institutional review board of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health Clinical Center. The study was registered in ClinicalTrials.Gov (#NCT00023322). Pegylated interferon alfa-2a (Peginterferon) was provided by Hoffman La Roche (Genentech) under a Clinical Trial Agreement with the NIDDK. Genentech did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Administration of peginterferon was conducted under an Investigational New Drug Application (IND # BB-10101) held by JHH.

Definition of Endpoints and Response

The primary histological endpoint of the study was defined as improvement in hepatic histology after 144 weeks of peginterferon therapy. Histological response was defined as a decrease in disease activity by ≥3 points using the modified histological activity index (HAI) scale without worsening of fibrosis (Ishak). A virological response (VR) to peginterferon therapy was defined as the inability to detect HDV RNA in serum by quantitative measurements. The primary
virological endpoint of the study was a complete virological response (CVR) and was defined as the combination of HDV virological response with HBsAg seroconversion. HBsAg seroconversion was defined as loss of HBsAg (negative on qualitative test or <1 IU/mL on quantitative test) and appearance of anti-HBs using a qualitative test.

Secondary endpoints included (i) improvement in histology after 48 weeks of peginterferon therapy, (ii) loss of HDV RNA from serum (undetectable = <100 genome equivalents (GE)/mL) at weeks 48, 144 and 260 (maintained virological response), (iii) loss of HBsAg from serum at weeks 48, 144 and 260, (iv) loss of detectable HDV antigen staining in the liver at weeks 48, 144 and 260, (v) normalisation of serum ALT (<41 U/mL) at weeks 48, 144 and 260 (maintained biochemical response), (vi) changes in hepatic venous pressure gradient (HVPG) measurements and their relationship with hepatic histology.

**Study design and dosing of peginterferon**

Patients were admitted to the NIH Clinical Center to start treatment with peginterferon 180 µg/week and had blood samples drawn at 6, 12, 18, 24, 48, 72 h after treatment initiation, followed by weekly out-patient visits for the first month and visits every 4–8 weeks thereafter. Serum samples were stored in −80°C. Transjugal liver biopsies with measurement of HVPG were performed at weeks 0, 48, 144 and 260.

During treatment, the peginterferon dose could be increased or decreased based on effect and tolerance. Following the initial 24 weeks, the dose could be escalated up to 360 µg/week if an effect was not seen at a lower dose, or decreased as needed for toxicity and tolerance. Efficacy was assessed by ALT and changes were in increments or decrements of 45 or 90 µg/week every 16–24 weeks (Figure S1). ALT was chosen to represent response as serum HDV RNA results were not available in real time. At the week 48 biopsy, patients without a ≥3 point improvement in the HAI inflammatory score (without worsening of fibrosis score) or a 1 point improvement in Ishak fibrosis score were considered nonresponders. Therapy was discontinued for: (i) intolerance to peginterferon, (ii) lack of histological response at 1, 3 and 5 years (a maintained histological response) or (iii) a complete virological response (defined as the loss of HDV RNA and HBsAg seroconversion). Those with complete virological response or virological response were followed after therapy in a protocolised manner for a year after stopping therapy.

In patients with concurrent active HBV infection (HBV DNA >10 000 copies/mL), nucleoside analogue therapy was instituted to suppress hepatitis B.

**Virological assays**

Quantitative measurement of serum HDV RNA level was performed by qPCR on stored samples with a lower limit of detection of 100 GE/mL (National Genetics Institute, Los Angeles, CA, USA).

Qualitative HBsAg testing was performed with the FDA approved VITROS® HBsAg assay (Ortho-Clinical Diagnostics, Raritan, NJ, USA) per manufacturer’s recommendations with a signal/cut-off ratio of 1.0. Quantitative HBsAg (qHBsAg) levels were measured on stored serum samples in a single batch, using the Elecsys HBsAg II Quant assay (Roche Diagnostics, Indianapolis, IN, USA) with a lower limit of detection of 0.055 IU/mL.

**Genetic analysis**

Genomic DNA was extracted from whole blood using the Qiagen Flexigene DNA Kit (Qiagen, Valencia, CA, USA) for 10 patients who provided consent for DNA analysis. Allelic discrimination for the IL28B-associated rs12989760 SNP, associated with interferon responsiveness in hepatitis B and C,19–22 was performed utilising the Taqman Custom SNP Genotyping Assay (Applied Biosystems, Foster City, CA, USA) on an ABI 7500 Real-Time PCR System (Applied Biosystems).

**Statistical analysis**

The slope of decline of HDV and HBsAg levels was calculated by linear regression using all available log-transformed data points from baseline to week 4. The week 12 decline was calculated by subtracting week 12 results from baseline. When week 12 results were not available, they were estimated using data from the previous and subsequent visits. Statistical analyses were performed using SPSS Statistics v. 19 (IBM, Armonk, NY, USA). Statistical significance was assessed using nonparametric tests.

**RESULTS**

**Patient population**

Between October 2002 and June 2006, 13 patients were recruited with characteristics summarised in Table 1. All patients had bridging fibrosis and only one patient had HBV DNA values above 10 000 IU/mL. One patient had an untypeable genotype and HDV RNA levels, and was thus excluded from the HBsAg and HDV RNA quantitative analyses. One patient dropped out after 7 weeks of
therapy due to social reasons. Two patients died while enrolled in the study. One was diagnosed with hepatocellular carcinoma (HCC) at week 81 of treatment (at which time treatment was withdrawn) and later died from HCC complications. The patient was reported to have bridging fibrosis on his baseline biopsy but had thrombocytopenia and markedly abnormal HVPG suggesting actual cirrhosis. The other patient had confirmed cirrhosis and Crohn’s disease and was off peginterferon therapy for 6 months due to a bacterial foot infection, when he developed herpes colitis which precipitated hepatic decompensation and death.23

Patients were treated for a median of 140 weeks (6–260) with an average weekly peginterferon dose of 180 µg/week (excluding treatment interruptions). The overall flow of patients is described in Figure 1. Dose reductions below 180 µg/week were required in three patients because of bone marrow suppression. Three patients were treated with a maximal dose of 225 µg/week and another three with doses up to 270 µg/week, and were able to tolerate the high dose for prolonged durations (up to 2 years). No patient was escalated to the highest permitted dose of 360 µg/week.

Treatment responses

Biochemical response. Six of 12 patients treated for >6 months achieved normalisation of ALT (<31 U/L), on at least one occasion while on therapy. In these six patients, the median time to ALT normalisation was 18 weeks (range 4–188, Figure 2). However, only three patients maintained a long-term biochemical response.

Histological Outcomes

After 1 year of therapy, histological inflammation decreased significantly from baseline [median HAI: 10 (7–14) to 7 (5–10), P = 0.01]. The HAI score declined in 10 patients, and was unchanged or worsened in two (Figure 3a). After 3 years of therapy, liver biopsies were obtained in five patients and continued to be lower than baseline [median HAI: 7 (5–13)]. At the end 5 years of therapy, liver biopsies were obtained in four patients and HAI scores continued to be lower than baseline [median HAI: 7.5 (4–8)]. After 1, 3 and 5 years of therapy, histological fibrosis did not change significantly (Figure 3b).
Overall histological response was achieved by six (50%) of 12 patients at 1 year. All patients who developed histological response at year 1 continued to meet the criterion for response at years 3 and 5.

**HVPG measurements**

Paired HVPG measurements were obtained in 11 patients at baseline and after the first year of therapy. After 1 year, the median HVPG decreased from 11.1 ± 6.4 mmHg to 8.1 ± 3.5 (P = 0.085). Of these 11 patients, seven (64%) had improved HVPG by 1–13 mmHg, three (27%) worsened by 1 mmHg and one patient had no change (Figure 3c).

After 3 years of therapy, five patients had paired HVPG measurements, with a mean of 6.2 ± 3.5 mmHg. When compared with their own HVPG at year 1, the five patients experienced a change of −1 ± 2 mmHg. At year 5 of therapy, four patients had HVPG obtained and no additional improvement was seen.

**Treatment safety**

Three patients required treatment interruption due to a serious adverse event, two of which were possibly related to peginterferon. One patient (mentioned previously) had a soft tissue infection of his foot requiring hospitalisation and surgical debridement. Following treatment interruption, his infection and resultant ulcers healed. This patient later succumbed to herpes colitis as previously described.\(^2\) Another patient developed an autoinflammatory syndrome after 192 weeks of treatment, characterised by fevers, headaches and intermittent confusion. A thorough workup was unable to identify the specific cause of the patient’s autoinflammatory syndrome. Treatment was stopped and his symptoms subsequently resolved. He was restarted on peginterferon at week 200 and did not have recurrence of symptoms and eventually achieved and maintained a VR. A third patient developed subarachnoid haemorrhage from an arteriovenous malformation at week 4 of treatment. Following successful therapy, peginterferon was resumed and she eventually achieved a CVR.
Two patients required dose reduction due to cytopaenias (one anaemia and one anaemia/thrombocytopaenia).

Kinetics of response

Several distinct patterns of virological response are demonstrated in Figure 4.

Complete virological responders. Of the 12 patients treated for at least 6 months, three patients achieved a CVR after 24, 37 and 202 weeks of treatment (Figure 4a–c) by demonstrating a continuous decline in HDV RNA until it was undetectable and HBsAg seroconversion. HBsAg loss and appearance of anti-HBs occurred simultaneously and only in patients with a VR. Two of these three patients also had a biochemical response. Therapy was discontinued 12–36 weeks after loss of HBsAg, and in all three patients, HBsAg and HDV RNA remained undetectable for the duration of follow-up (58–246 weeks after stopping therapy). For two subjects (Figure 4a,b), this occurred rapidly (decline slopes of 0.29 and 0.52 log_{10}/week in the first 4 weeks), while a third subject (Figure 4c) had an initial comparable rapid decline of 0.24 log_{10}/week during the first 4 weeks that slowed to an average overall slope of decline of 0.03 log_{10}/week. HBsAg levels declined in all three patients, lagging behind the HDV RNA decline, and were <100 IU/mL at the time of HDV RNA negativity and <1 IU/mL subsequently. ALT decline did not correlate well with virological decline, and in one subject ALT levels did not improve despite HDV RNA and HBsAg loss (Figure 4b).

Virological Response and relapse. Two patients (Figure 4d,e) became HDV RNA negative but subsequently had virological breakthrough while on treatment. One of the two (Figure 4d) had a relatively fast virological response (decline slope of 0.29 log_{10}/week in the first 4 weeks) and became HDV RNA negative by week 20 of treatment. However, HDV RNA levels subsequently rose and reached baseline levels despite continued peginterferon treatment. HBsAg levels also fell and were transiently undetectable, but later rose towards baseline. The other subject (Figure 4e) had a rapid decline in HDV RNA levels (0.21 log_{10}/week in the first 4 weeks), which reached the lower limit of detection (100 GE/mL) by week 45. However, HDV RNA levels then rose despite continued treatment only to decline again to undetectable levels by week 129 of treatment, accompanied by marked decline in HBsAg titre. Shortly thereafter, the patient developed an autoimmune inflammatory syndrome that required a discontinuation of treatment on week 177. This treatment withdrawal resulted in a rise, initially in HBsAg, followed by HDV RNA and finally by ALT (35 weeks after stopping treatment); there was a rapid and synchronous response of all three markers to reinstitution of peginterferon on week 202, followed by achievement and maintenance of a virological response (Figure S2). Thus, this patient exhibited a flare of disease (rise in ALT to >5 times baseline) concurrent with the
Figure 4 | (Continued).
virological breakthrough early on treatment which was followed by loss of HDV RNA (possibly a ‘clearance flare’) and another flare when therapy was temporarily suspended (‘withdrawal flare’).

**Nonresponse.** Other subjects (Figure 4f-g) never became HDV RNA negative despite an initial response (4 week slope of 0.21 and 0.27 log₁₀/week, respectively), and demonstrate plateau or rebounding of HDV levels while on prolonged therapy. Although ALT levels improved compared to baseline, they did not fall into the normal range and neither liver histology scores nor HVPG measurements improved at subsequent evaluation.

After the initial declines in HDV RNA levels during the first 24 weeks of treatment, decreases or increases in the dose of peginterferon were not clearly associated with changes in HDV RNA levels.

**Predictors of response**

Baseline and on-treatment features were evaluated for their ability to predict virological response to treatment in the 11 subjects who had HDV RNA measurements for at least 8 weeks (Table 2). The three complete responders demonstrated a trend towards lower alkaline phosphatase, bilirubin and histological fibrosis scores at baseline and numerically lower HVPG and platelet count, consistent with milder disease, though statistical significance could not be reached due to the small number. Age, ALT, HBV and HDV viral levels, HBsAg titre and histological activity did not predict complete response. When comparing patients who had any virological response on treatment to those who did not (Table 2), responders had lower bilirubin levels and HBsAg levels and a trend towards lower ALT. The IL28B-associated rs12989760 genotype frequency was similar for responders and nonresponders.

When assessing early kinetics of response as predictors of overall virological outcomes (Table 3), the slopes of decline of HDV RNA and HBsAg during the first 4 weeks were similar for responders and nonresponders. In fact, all patients had an initial virological response with a 4-week decline in HDV RNA >0.5 log₁₀ (mean 0.97 ± 0.35 log₁₀), irrespective of their final outcome. By week 12 of treatment, the magnitude of decline of HBsAg was greater for patients who responded to treatment and became HDV RNA negative. However, there was still an overlap between responders and nonresponders.

**Table 2 | Comparison of baseline predictors of response with patients that achieved a complete virological response or a virological response**

<table>
<thead>
<tr>
<th></th>
<th>Complete virological response*</th>
<th>Virological response†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes (n = 3)</td>
<td>No (n = 8)</td>
</tr>
<tr>
<td>Age (years)‡</td>
<td>49 ± 4</td>
<td>41 ± 14</td>
</tr>
<tr>
<td>ALT (U/L) †</td>
<td>98 ± 93</td>
<td>181 ± 155</td>
</tr>
<tr>
<td>Alkaline Phosphatase (U/L) †</td>
<td>62 ± 10</td>
<td>123 ± 60</td>
</tr>
<tr>
<td>Bilirubin (mg/dL) ‡</td>
<td>0.6 ± 0.2</td>
<td>1 ± 0.4</td>
</tr>
<tr>
<td>HBV DNA &gt;1000 IU/mL (%)</td>
<td>1 (33%)</td>
<td>1 (13%)</td>
</tr>
<tr>
<td>HBsAg (log₁₀ IU/mL)†</td>
<td>3.4 ± 0.6</td>
<td>3.8 ± 0.6</td>
</tr>
<tr>
<td>HDV RNA (log₁₀ GE/mL) †</td>
<td>6.2 ± 1.2</td>
<td>6.9 ± 1.2</td>
</tr>
<tr>
<td>HAI Inflammation (median)</td>
<td>12 (7–14)</td>
<td>12 (7–14)</td>
</tr>
<tr>
<td>Fibrosis (median, range)</td>
<td>3 (3–3)</td>
<td>4 (3–6)</td>
</tr>
<tr>
<td>Platelets (1000/µL) ‡</td>
<td>153 ± 71</td>
<td>138 ± 54</td>
</tr>
<tr>
<td>HVPG (mmHg) ‡</td>
<td>8 ± 0</td>
<td>11 ± 7</td>
</tr>
<tr>
<td>rs12979860 genotype (n = 10)</td>
<td>1 (50%)</td>
<td>4 (50%)</td>
</tr>
<tr>
<td>CC</td>
<td>1 (50%)</td>
<td>4 (50%)</td>
</tr>
<tr>
<td>CT</td>
<td>1 (50%)</td>
<td>4 (50%)</td>
</tr>
</tbody>
</table>

* Complete virological response = Undetectable HDV RNA in serum and seroconversion of HBsAg.

† Virological response = Undetectable HDV RNA in serum.

‡ Mean (range).

§ Mann–Whitney test.

¶ Fisher’s exact test.
nonresponders and even more so, between complete responders and subject with virological breakthrough (Figure 5). Detailed modelling of the kinetics of response is reported separately.24

**DISCUSSION**

In our study, four of 12 patients (30%) with chronic HDV achieved and maintained a VR during long-term (5 years) peginterferon therapy. Of these four patients, three achieved a CVR. The maintained VR rate achieved in our study corresponds to other studies that have evaluated peginterferon therapy for HDV with rates ranging from 17% to 43% after 24 weeks of therapy, 21–48% with therapy ranging from 48 to 96 weeks.25–32 Similar to a recent publication, there has been no evidence of relapse of our patients who achieved a CVR, some of which have been followed up to 246 weeks after stopping therapy.33 Interestingly, two of the four patients achieved a CVR prior to the completing 1 year of therapy (weeks 24 and 37) and the other one at week 202. Given the overall timeframe that the CVRs occurred, along with the poor CVR rates for the entire group after 5 years of therapy, this possibly suggests that extending peginterferon therapy for HDV beyond 1 year does not necessarily improve response, although there may be individual patients that may benefit. In addition, treatment of chronic HDV with peginterferon for 5 years does not seem to improve the chances of HDV clearance.

On histological evaluation, the greatest improvement in hepatic inflammation was seen after 1 year of peginterferon therapy. Although this improvement was maintained on years 3 and 5 of the study, as compared to baseline, statistical significance was not achieved. These results could be due to the low numbers of patients who underwent liver biopsies at years 3 and 5 (five and four patients, respectively). Alternatively, these results could signify that the effects of peginterferon on HDV may peak prior to 1 year of therapy without further improvement on histological inflammation. In a case report describing 12 years of interferon therapy in a patient with HDV, Lau et al. described a greater decrease in

---

**Table 3 | On-treatment predictors of response**

<table>
<thead>
<tr>
<th></th>
<th>Complete virological response*</th>
<th>Virological response†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes (GE log10/mL/week)</td>
<td>Yes (IU log10/mL)</td>
</tr>
<tr>
<td>HDV RNA 4 week slope</td>
<td>–0.35 ± 0.15</td>
<td>–0.35 ± 0.15</td>
</tr>
<tr>
<td>HDV RNA week 12 decline</td>
<td>3.6 ± 3.3</td>
<td>3.0 ± 2.5</td>
</tr>
<tr>
<td>HBsAg 4 week slope</td>
<td>–0.04 ± 0.08</td>
<td>–0.02 ± 0.06</td>
</tr>
<tr>
<td>HBsAg week 12 decline</td>
<td>1.7 ± 1.8</td>
<td>1.5 ± 1.3</td>
</tr>
</tbody>
</table>

* Complete virological response = Undetectable HDV RNA in serum and seroconversion of HBsAg.
† Virological response = Undetectable HDV RNA in serum.
‡ Mann–Whitney test.
§ Mean ± s.d.
histological hepatic inflammation during the first 4 months of therapy as compared to 3 years of therapy.\textsuperscript{13}

One of the strengths of this study was the availability of HVPG measurements at years 1, 3 and 5 to provide additional information on the effects of long-term peginterferon therapy for chronic HDV. In general, HVPG showed a trend towards improvement after 1 year of peginterferon therapy. Of patients, 64\% had improvement in HVPG, while three had worsening of HVPG by 1 mmHg. Other studies have reported minor variations in repeated portal pressure measurements which may be due to the heterogeneity of sinusoidal involvement for a given disease process and also reflecting that cirrhosis is not a homogenous disease.\textsuperscript{16, 34\textendash}36 A more recent study comparing the use of balloon catheters and straight catheters for HVPG showed that on repeated sequential repeated measurements a difference of \( \pm 1 \text{mmHg} \) is within one standard deviation of the mean, and thus not a significant difference.\textsuperscript{37} Therefore, we feel that the lack of statistical significance may be due to the low numbers of patients evaluated. Further studies utilising HVPG as a measurement of response with larger numbers may elaborate on HVPGs usefulness, particularly as this has been shown in chronic hepatitis B infection.\textsuperscript{38}

In this study, we also evaluated quantitative HBsAg levels in HDV patients while on therapy. In patients with chronic HBV mono-infection, lower HBsAg levels have been associated with a higher rate of HBsAg clearance.\textsuperscript{39, 40} In a retrospective HDV study and a case report evaluating HBsAg levels while on interferon, investigators noted a slower decline in HBsAg levels as compared to HDV RNA levels in individuals who became HDV RNA undetectable.\textsuperscript{41, 42} In our study, we corroborate prior descriptions that HBsAg levels decline while on peginterferon therapy and demonstrate similar trends of decline for HBsAg and HDV RNA levels. We show a difference between responders and nonresponders in early HBsAg decline, but this could be driven by two early responders (Figures 4a,b) in our study. However, qualitative assessment of response patterns demonstrates that when HDV RNA becomes negative, it is accompanied by a precipitous drop in HBsAg levels, even in late response (Figure 4c, e). A sustained response was only achieved if HBsAg became undetectable (by qualitative assay). Furthermore, a well-defined case of withdrawal flare (Figures 4e, S2) clearly showed a rise in HBsAg preceding the rise in HDV RNA titres. Given the small numbers in this study, these findings should be confirmed in a larger sample of patients.

For a prolonged-therapy approach to be feasible, one would need to show a time-dependent benefit for treatment prolongation, its safety and suggest early stopping rules. Although our data did not show a clear benefit of extending treatment, it should be noted that one of the subjects (Fig. 4c) did achieve a complete virological response after nearly 4 years of treatment, suggesting some patients require prolonged treatment to respond. Despite that, we were not able to show a clear benefit from prolonging treatment, and could not identify early stopping rules; at least using fixed parameters that would be readily available to clinicians (such as week 4 and 12 declines), though mathematical modelling may suggest other stopping rules\textsuperscript{24} these reflect the obvious main limitation of the study, the small number of subjects enrolled and the small number of individuals reaching the 3- and 5-year time points for liver biopsy and HVPG evaluation.

In general, patients tolerated therapy well with varying doses of peginterferon at doses up to 270 \( \mu \text{g/week} \). Although dose adjustment for cytopenias was needed in three patients, only two subjects experienced a serious interferon-related adverse event (one with foot infection and another who developed an autoimmune inflammatory syndrome) that required temporary cessation of therapy. Thus, peginterferon therapy extending to 5 years appears to be safe and tolerable in most patients with chronic HDV infection.

In summary, treatment of chronic HDV with peginterferon remains unsatisfactory despite increasing of the duration of treatment out to 5 years and/or increasing peginterferon dosage up to 270 \( \mu \text{g/week} \). In addition, the long-term impact of prolonged peginterferon exposure in patients with HDV has not been adequately evaluated. It may be the quantitative measures of HBsAg and HDV RNA will prove to be biomarkers of early response, however this needs to be validated with additional studies. With ongoing clinical trials evaluating prenylation inhibitors against HDV, the field is eagerly awaiting new
Long-term peginterferon therapy of delta hepatitis

Declaration of personal interests: None.

Declaration of funding interests: This research was funded by the Intramural Research Programs of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Cancer Institute (NCI) of the National Institutes of Health (NIH). Peginterferon alfa-2a was provided by Hoffman La Roche (Genentech) under a Clinical Trial Agreement with the NIDDK.

SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article:

Figure S1. This figure describes the peginterferon dose modification schedule while patients were on therapy.

Figure S2. Response pattern of patient described in Figure 4e during the period of peginterferon withdrawal which describes a withdrawal flare with a rise in HBsAg preceding the rise in HDV RNA titres.

REFERENCES
3. Glenn JS, Marsters JC Jr, Greenberg RM, PS, JA, DEK, MGG, TJL, JHH. Statistical analysis: TH, YR, CK, SC, VH, RC, RM, PS, JA, DEK, MGG, TJL, JHH. Drafting: TH, YR, CK. Critical revision: SC, VH, RC, RM, PS, JA, DEK, MGG, TJL, JHH. All authors approved the final version of this manuscript.

AUTHORSHIP
Guarantor of the article: Theo Heller.

Author contributions: Study concept & design: TH, YR, CK, JHH. Acquisition of data: TH, YR, CK, VH, RC, RM, MGG, TJL, JHH. Analysis/interpretation: TH, YR, CK, SC, VH, RC, RM, PS, JA, DEK, MGG, TJL, JHH. Drafting: TH, YR, CK. Critical revision: SC, VH, RC, RM, PS, JA, DEK, MGG, TJL, JHH. Statistical analysis: TH, YR, CK. Supervision: JHH, TJL. All authors contributed to the intellectual content of this paper.

ACKNOWLEDGEMENTS
We thank Drs Richard Batrla-Utermann and Michael Leuther (Roche Diagnostics) and Dr Barbara Body (LabCorp) for qHBsAg testing; and Ms Ronda Sapp and the staff of the NIDDK Clinical Services Core. We also thank Dr Nigel Puck for his support.

therapeutic modalities against the most feared and rapidly progressive chronic viral hepatitis currently known.

We thank Drs Richard Batrla-Utermann and Michael Leuther (Roche Diagnostics) and Dr Barbara Body (LabCorp) for qHBsAg testing; and Ms Ronda Sapp and the staff of the NIDDK Clinical Services Core. We also thank Dr Nigel Puck for his support.

REFERENCES
3. Glenn JS, Marsters JC Jr, Greenberg RM, PS, JA, DEK, MGG, TJL, JHH. Statistical analysis: TH, YR, CK. Critical revision: SC, VH, RC, RM, PS, JA, DEK, MGG, TJL, JHH. All authors approved the final version of this manuscript.

AUTHORSHIP
Guarantor of the article: Theo Heller.

Author contributions: Study concept & design: TH, YR, CK, JHH. Acquisition of data: TH, YR, CK, VH, RC, RM, MGG, TJL, JHH. Analysis/interpretation: TH, YR, CK, SC, VH, RC, RM, PS, JA, DEK, MGG, TJL, JHH. Drafting: TH, YR, CK. Critical revision: SC, VH, RC, RM, PS, JA, DEK, MGG, TJL, JHH. Statistical analysis: TH, YR, CK. Supervision: JHH, TJL. All authors contributed to the intellectual content of this paper.

ACKNOWLEDGEMENTS
We thank Drs Richard Batrla-Utermann and Michael Leuther (Roche Diagnostics) and Dr Barbara Body (LabCorp) for qHBsAg testing; and Ms Ronda Sapp and the staff of the NIDDK Clinical Services Core. We also thank Dr Nigel Puck for his support.

therapeutic modalities against the most feared and rapidly progressive chronic viral hepatitis currently known.

We thank Drs Richard Batrla-Utermann and Michael Leuther (Roche Diagnostics) and Dr Barbara Body (LabCorp) for qHBsAg testing; and Ms Ronda Sapp and the staff of the NIDDK Clinical Services Core. We also thank Dr Nigel Puck for his support.

REFERENCES
3. Glenn JS, Marsters JC Jr, Greenberg RM, PS, JA, DEK, MGG, TJL, JHH. Statistical analysis: TH, YR, CK. Critical revision: SC, VH, RC, RM, PS, JA, DEK, MGG, TJL, JHH. All authors approved the final version of this manuscript.

AUTHORSHIP
Guarantor of the article: Theo Heller.

Author contributions: Study concept & design: TH, YR, CK, JHH. Acquisition of data: TH, YR, CK, VH, RC, RM, MGG, TJL, JHH. Analysis/interpretation: TH, YR, CK, SC, VH, RC, RM, PS, JA, DEK, MGG, TJL, JHH. Drafting: TH, YR, CK. Critical revision: SC, VH, RC, RM, PS, JA, DEK, MGG, TJL, JHH. Statistical analysis: TH, YR, CK. Supervision: JHH, TJL. All authors contributed to the intellectual content of this paper.

ACKNOWLEDGEMENTS
We thank Drs Richard Batrla-Utermann and Michael Leuther (Roche Diagnostics) and Dr Barbara Body (LabCorp) for qHBsAg testing; and Ms Ronda Sapp and the staff of the NIDDK Clinical Services Core. We also thank Dr Nigel Puck for his support.

therapeutic modalities against the most feared and rapidly progressive chronic viral hepatitis currently known.

We thank Drs Richard Batrla-Utermann and Michael Leuther (Roche Diagnostics) and Dr Barbara Body (LabCorp) for qHBsAg testing; and Ms Ronda Sapp and the staff of the NIDDK Clinical Services Core. We also thank Dr Nigel Puck for his support.

REFERENCES
3. Glenn JS, Marsters JC Jr, Greenberg RM, PS, JA, DEK, MGG, TJL, JHH. Statistical analysis: TH, YR, CK. Critical revision: SC, VH, RC, RM, PS, JA, DEK, MGG, TJL, JHH. All authors approved the final version of this manuscript.

AUTHORSHIP
Guarantor of the article: Theo Heller.

Author contributions: Study concept & design: TH, YR, CK, JHH. Acquisition of data: TH, YR, CK, VH, RC, RM, MGG, TJL, JHH. Analysis/interpretation: TH, YR, CK, SC, VH, RC, RM, PS, JA, DEK, MGG, TJL, JHH. Drafting: TH, YR, CK. Critical revision: SC, VH, RC, RM, PS, JA, DEK, MGG, TJL, JHH. Statistical analysis: TH, YR, CK. Supervision: JHH, TJL. All authors contributed to the intellectual content of this paper.

ACKNOWLEDGEMENTS
We thank Drs Richard Batrla-Utermann and Michael Leuther (Roche Diagnostics) and Dr Barbara Body (LabCorp) for qHBsAg testing; and Ms Ronda Sapp and the staff of the NIDDK Clinical Services Core. We also thank Dr Nigel Puck for his support.


